In preclinical models, researchers observed that AOD9604 does not stimulate IGF-1 production or activate the growth hormone receptor, distinguishing it from full-length hGH
Experimental Biology and Medicine (Maywood)
Safety Risks Associated with Certain Bulk Drug Substances Nominated for Use in Compounding
Sahu M, Sharma AK, Sharma G, Kumar A, Nandave M, Babu V
The safety and effectiveness of EGRIFTA WR (11.6 mg/vial formulation) has been established based on adequate and well controlled studies with EGRIFTA (1 mg/vial formulation), as well as a demonstration of comparable bioavailability between the 1.28 mg EGRIFTA WR dose (11.6 mg/vial formulation) and the 2 mg EGRIFTA dose (1 mg/vial formulation) [see Clinical Pharmacology (12.3)]
Experts do not generally recommend discontinuing the use of metformin for people with new cases of vitamin B12 deficiency